Editorial Board ::: Current Drug Delivery

ISSN: 1875-5704 (Online)
ISSN: 1567-2018 (Print)

Volume 14, 8 Issues, 2017

Download PDF Flyer

Current Drug Delivery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Xing-Jie Liang
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety
National Center for Nanoscience and Technology of China

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.516
5 - Year: 2.338

Editorial Board


Xing-Jie Liang (Biography
Xing-Jie Liang

Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. Dr. Liang also holds a postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Currently Dr. Liang is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He has published more than 80 scientific publications..


CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety
National Center for Nanoscience and Technology of China


Yoshihiro Hayakawa
Faculty of Engineering Department of Applied Chemistry Aichi Institute of Technology 1247 Yachigusa, Yakusa-cho
Toyota, Aichi 470-0392

Manmohan Singh
Novartis Vaccines Vaccine Delivery Group 4560 Horton Street, MS 4.3
Emeryville, CA 94608

David S. Jones (Biography
David S. Jones

David Jones, Professor of Biomaterial Science at Queen’s University Belfast and Pro-Vice-Chancellor for Education and Students. He holds BSc (1st class honours) in Pharmacy (1985), a PhD in Pharmaceutics (1988), in 2006, a DSc., all from Queens University of Belfast. More recently (2014) he gained a BA (1st class honours) in Mathematics and Statistics from the Open University. Since 1999 he holds a personal Chair (in Biomaterial Sciences) at the School of Pharmacy, Queens University of Belfast. His research concerns the characterisation, formulation and engineering of pharmaceutical materials/dosage forms and biomedical devices. He is the author of three textbooks, 10 patents and over 400 research papers.


School of Pharmacy,Queen's University of Belfast,Medical Biology Centre,97, Lisburn Road
Belfast, BT9 7BL

Hiraku Onishi
Department of Drug Delivery Research Hoshi University, 2-4-41, Ebara Shinagawa-ku
Tokyo, 142-8501

Assistant Editor(s):

J. Blanchfield
School of Molecular and Microbial Sciences University of Queensland

Associate Editors:

Cristina Bonferoni (Biography
Cristina Bonferoni

Dr Maria Cristina Bonferoni Graduated in 1984 and got PhD in 1991 in Pharmaceutical Chemistry and Technology. She is associate professor since 2001, at the Department of Drug Sciences, University of Pavia. The research interests concern pharmaceutical development of conventional and controlled release formulations. Early work involved the study of hydrophilic polymers for oral matrix tablets. Swelling/erosion and diffusion/dissolution processes occurring in hydrophilic matrices have been studied and related to polymer rheological behaviour (viscosity and viscoelasticity) under different conditions of pH and ionic strength. Other research interest involved mucoadhesion mechanisms, development of mucoadhesive dosage forms and of methods to measure mucoadhesion properties. Dr Bonferoni is author of about 140 scientific papers, 12 patents, 12 book chapters.


University of Pavia

Sam T. Mathew
Research & Development Biocon Ltd
Bangalore, Karnataka

Xue Xue (Biography
Xue Xue

Dr. Xue Xue obtained her Ph.D at National Center for Nanoscience and Technologies, Chinese Academy of Sciences, with her mentor Dr. Xing-jie Liang. From 2012 to 2014, she studied in New York University as a visiting scholar. Then she was an assistant professor with Dr. Hong Zhang at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. Dr. Xue is currently a principle investigator in State Key Laboratory of Medicinal Chemical Biology/College of Pharmacy, and lab chief of Laboratory of Theranostic Nanomedicine in Nankai University. In recent five years, she has authored over 15 SCI-indexed papers with total IF > 150.


Nankai University
P.R. China

Editorial Board Members:

A. Agrawal (Biography
A. Agrawal

Dr. Ajay K Agrawal received his doctorate in Chemistry, and conducted his post- doctoral research in the Faculty of Medicine, University of Alberta, Canada and Molecular Cell Pathology, Royal Free Hospital, London on novel targeted cancer drug delivery therapeutics and imaging systems based on pegylation. He has been in the board of directors of several biotech and pharma companies in UK, Europe and USA, including the development board of Buckingham Medical School. Dr. Agrawal has been in the editorial board of number of journals, published by Bentham Science Publishers. One of his invited review articles was cited in the “Current Awareness in Biomedicine: Drug Targeting Bulletin” after being scanned in over 2,500 journals.


DyoDelta Biosciences Ltd

H.O. Alpar
University of London

H.A.E. Benson
Curtin University of Technology

B. Boyd
Monash University (Parkville Campus)

M. R. Doschak
University of Alberta
Edmonton, AB

H. Gu
Vanderbilt University
Nashville, TN

H. Ichikawa
Kobe Gakuin University

H.-W. Kim (Biography
H.-W. Kim

Dr. Hae-Won Kim received his PhD from the Soul National University, South Korea, in 2002. He was a visiting scientist at the National Institute of Standards and Technology (NIST, 2000), and a Postdoctoral Fellow at University College London (UCL) Eastman Dental Institute (2003-2004) and Seoul National University Advanced Materials Research Institute (2004-2005). His research interests include tissue engineering, stem cell engineering, biointerface control and therapeutic scaffolds for muscle, nerve, blood vessel, bone and tooth structures. He is currently a Director of the Institute of Tissue Regeneration Engineering (ITREN), and leads BK21+ Nanobiomedical Science Department. He is currently the editor-in-chief of the Journal of Tissue Engineering. He has published over 350 peer-reviewed papers.


Dankook University
Cheonan, 330-714
Republic of Korea

M. Lebl
Illumina, Inc.
San Diego

A. Margaritis
The University of Western Ontario, London

F. Peri (Biography
F. Peri

Francesco Peri is Professor of Organic and Medicinal Chemistry at the Department of Biotechnology and Biosciences, University of Milano-Bicocca, Italy. his research focused on the rational design and synthesis of new molecules (mainly glycolipids) capable to interact with innate immunity receptors MD-2 and CD14, thus interfering with the molecular processes of TLR4 activation and signaling. Several generation of TLR4 antagonists were patented and some of these compounds (IAXO molecules, Adipogen) are now commercially available as selective TLR4 blockers. He coordinates the Marie Curie ETN EU project 642157 (2015-2019)– TOLLerant (Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach), network consists of 8 academic and 2 industrial full partners representing 5 countries all across Europe and 3 associate partners, 2 from Europe and one from USA.


University of Milano

L. Prokai
University of North Texas Health Science Center

B. Rihova
Institute of Microbiology
Czech Republic

P. Rovero
Universita' di Firenze

M. Skwarczynski (Biography
M. Skwarczynski

Dr M. Skwarczynski received a Master degree in biotechnology and a PhD in chemistry from Wroclaw University of Technology (Poland). In 2004 he was awarded Japan Society for the Promotion of Science Postdoctoral Fellowship, and a grant to conduct research on paclitaxel.His research interest lies in the general area of medicinal chemistry and more recently in the development of nanomaterials for biomedical applications, vaccine delivery strategies, including design, chemoselective synthesis, conformational studies, and immunological properties of lipopeptide and polymer assembled multivalent vaccine candidates. He is author of over 70 journal articles and book chapters.


The University of Queensland
St Lucia, QLD

V. Torchilin (Biography
V. Torchilin

Vladimir P. Torchilin, Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Mass. He graduated from the Moscow University with MS in Chemistry, and also obtained his Ph.D. and D.Sc. in Polymer Chemistry, Chemical Kinetics and Catalysis, and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. His main interests include drug delivery and targeting, nanomedicine, multifunctional, stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy, cancer immunology, novel imaging agents. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 10 books and holds more than 40 patents.


Northeastern University
Boston, MA

D.W. Wang
Huazhong University of Science and Technology (HUST)
Rep. of China 430030

X. Wu (Biography
X. Wu

Dr. Xiao Wu is a Research Scientist in Formulation Development at Eli Lilly and Company in the US where she serves as a technical lead in development of early and commercial phase pharmaceutical formulations. She received her pharmacy degree (2003) from Peking University in China and Ph.D. (2008) in Pharmaceutics from the University of Bath, UK. Her Ph.D. research work focused on skin barrier function characterization, transdermal drug delivery, enhancement of percutaneous absorption, the prediction and assessment of skin penetration and topical bioavailability and nanotechnology. She is the author and co-author of 14 publications, and presented her research at more than 10 national and international conferences.


Eli Lilly and Company
Greenfield, IN

H. Ai
National Engineering Research Center for Biomaterials, Sichuan University

P. Artursson (Biography
P. Artursson

Per Artursson is a professor in Dosage Form Design at the Department of Pharmacy, Uppsala University, Sweden where he heads the Drug Delivery research team. He is also Director for the Uppsala University drug optimization and pharmaceutical profiling platform within Science for Life Laboratories. His research aims at understanding drug absorption, distribution, metabolism and elimination (ADME) at the molecular and cellular level in order to deliver drugs more effectively via the oral route. He also investigates the effects of drug transporting proteins on drug disposition and drug interactions. He has published over 200 research articles and reviews, is highly cited and has received several international awards for his research.


Biomedical Centre

P. Blasi
Univ. of Camerino

S.T. Chen
Institute of Biological Chemistry

V. Ferro
University of Strathclyde

B. He
Sichuan University

T. Inazu
Tokai University

J. H. Kopeček
University of Utah (UT)
Salt Lake City

J. Li
National University of Singapore

L. Otvos (Biography
L. Otvos

Laszlo Otvos is Associate Editor for Current Protein and Peptide Science and Regional Editor for Protein and Peptide Letters. An organic chemist by education, he received his PhD degree from the Hungarian Academy of Sciences, Budapest in 1991 for developing novel chemical technologies in order to identify and characterize immunologically active peptides and processes in Alzheimer’s disease and anti-viral vaccine development. Later his research repertoire was extended to antimicrobial peptides and peptidic modulators of adipokine receptor responses focusing on cancer and cardiovascular/metabolic disease research. An author of more than 200 peer-reviewed papers with over 14,000 references to his publications, Laszlo Otvos is among the top 1% most cited researchers in the life science arena.


Audubon, PA

Y. Perrie (Biography
Y. Perrie

Dr. Yvonne Perrie is Chair Person in Drug Delivery within the University of Strathclyde. In 1998, she gained her PhD from the University of London investigating the role of liposomes for drug delivery. Dr. Perrie is an internationally recognised researcher with a strong track-record of high impact publications; with approximately 100 peer reviewed manuscripts and 5 textbooks. Her research is multi-disciplinary and is focused on the development of drug delivery systems to facilitate the delivery of drugs and vaccines, thus providing practical solutions for current healthcare problems.


University of Strathclyde

T. Rades
University of Otago
New Zealand

M. Roberts (Biography
M. Roberts

Michael (Mike) S. Roberts PhD DSc is a NHMRC Senior Principal Research Fellow, Professor of Therapeutics & Pharmaceutical Science at the University of South Australia; Professor of Clinical Pharmacology & Therapeutics at The University of Queensland and is Director of the Therapeutics Research Centre (TRC), based at the Princess Alexandra Hospital (Brisbane) and The Queen Elizabeth Hospital (Adelaide). His research outputs include: 7 books, more than 450 peer reviewed research publications, >50 book chapters; > 200 invited international talks and a leader of research teams funded by Australian and International Research bodies. He has recently been elected a Fellow of the Australian Academy of Health & Medical Science.


University of Queensland

F. Shakeel (Biography
F. Shakeel

Dr. Faiyaz Shakeel received a Master degree (M. Pharm) and a PhD in Pharmaceutics from Jamia Hamdard (Hamdard University, New Delhi, India). At Jamia Hamdard. In 2011, he was awarded Young Scientist Award from the Association of Pharmacy Professionals (APP). In March 2016, he has been promoted to Associate Professor at King Saud University. At King Saud University, He also had very good expertise in solubilization of drug molecules using cosolvency models. His research interest lies in the general area of Pharmaceutics and more recently in the development of nanoemulsions and self-nanoemulsifying formulations for therapeutic applications. He is author of over 180 journal articles and book chapter.


King Saud University
Saudi Arabia

C. Strachan
Faculty of Pharmacy

I.F. Uchegbu
University of Strathclyde

K.H. Weismuller
EMC Microcollections GmbH

N. Yuksel (Biography
N. Yuksel

Professor Yuksel is a pharmacist with a research focus on pharmaceutical technology. After graduation, she worked as a pharmacist at Ministry of Health and Social Services, General Directorate of Pharmaceuticals and Pharmacy for one year, then she became a research assistant in Ankara University Faculty of Pharmacy. She got her M.Sc. degree in 1998 and Ph.D. degree in 1995 at the Department of Pharmaceutical Technology in Ankara University Faculty of Pharmacy. In 1998, she worked as a postdoc fellow in Industrial Pharmacy Program at the University of Cincinnati Faculty of Pharmacy for one year. She worked as an assistant professor between 1999-2005; obtained the title of Associate Professor in 2005; and she became a Professor in 2010. Her research interests include formulation approaches for enhancing solubility of poorly soluble drugs, development of modified release dosage forms: semisolid matrix into hard gelatin capsules, tablets, polymeric microspheres; and nanoparticulate drug delivery systems including niosomes, proniosomes, polymeric micelles. She has about 45 scientific articles and 35 symposium presentations. She has several research grants from Turkish Scientific and Technological Research Council to support her research. She is editorial board member of the journals named “Current Drug Delivery”, “Drug Delivery Letters”, and “The Scientific World Journal”. She currently serves as a member of the advisory committee for generic drug products in Turkey Drug and Medicinal Device Agency.


Ankara University

R. Alany (Biography
R. Alany

Professor Raid Alany’s academic journey spans three continents; namely, Asia, Oceania and Europe. He received his PhD in ocular drug delivery from the University of Otago, Dunedin New Zealand in 2001; was appointed as a Lecturer at the School of Pharmacy, The University of Auckland, Auckland, New Zealand, in 2001. He joined Kingston University London as Professor (Chair) of Pharmaceutics in January 2011 and was appointed as Research Director for the School of Pharmacy and Chemistry in December 2013. Dr. Raid is an author on over 200 scientific research publications (papers and abstracts), a book and seven book chapters; he has attracted over $NZ 2M (£GBP 1M) in contestable research and enterprise funding.


School of Pharmacy and Chemistry, Kingston University

K.V. Barar (Biography
K.V. Barar

Dr. Kiran V. Barar is Senior Professor and HOD-Pharmacology at S.P.Medical College (SPMC), Bikaner, Rajasthan, India. She is also serving as Honorary Professor at “Albert Schiwtzer International University”(ASIU), Geneva, Switzerland since 2000. She has remained posted at RUHS-College of Medical Sciences, Jaipur (Newly recognized by MCI) for last Two years as an OSD & HOD to ESTABLISH the Dept. of Pharmacology. Dr.Kiran has been a Meritorious (Gold Medalist) throughout and Winner of various “Distinctions, Awards and Prizes” during her whole academic career. She has published about “80” papers including theses and has been an Editor, Reviewer and Writer/Columnist.


Rajasthan University of Health Sciences (RUHS) Bikaner

R. Borchardt
The University of Kansas
Lawrence, KS

F. Cilurzo
Università degli Studi di Milano

M. Foldvari
University of Saskatchewan
Saskatoon, SK

R.C. Hermida
University of Vigo

S. K. Jain
Dr. Hari Singh Gour University

M. Lane
School of Pharmacy, University of London

P. Malyala
Vaccine Chemistry & Formulations Novartis Vaccines 45 Sidney Street
Cambridge, MA

R. Panchagnula

R. Polt (Biography
R. Polt

R. Polt has embraced several relatively diverse scientific disciplines in his career, often running counter to the prevailing wisdom and advice. He studied Chemistry at IUPUI under the direction of Prof. Martin J. O’Donnell, where he was involved in the enantioselective alkylation of masked glycine anion and cation equivalents to produce the first of the “O’Donnell Schiff Bases.” (Ph2C=O + H2NCH2CO2CH2CH3 → Ph2C=NCH2CO2CH2CH3) An NSF Fellowship that took him to Columbia University where he studied with Prof. Gilbert J. Stork where he earned his Ph.D. in 1986, and then on to Prof. Dieter Seebach’s group in Zürich where he studied the alkylation of peptides in addition to glycine equivalents. Robin shifted his interests toward the synthesis and evaluation of glycopeptide drugs at the University of Arizona starting in 1988. His glycosylated neuropeptides showed excellent biological activity, extended stability in vitro and in vivo, and also cross the blood-brain barrier to produce central effects. Presently, Robin is involved in the study of glycolipid surfactants as drug delivery vehicles in addition to the glycopeptide drugs, which also possess surface activity, which is key to their distribution in vivo.


University of Arizona
Tucson, AZ

M.A. Repka
The University of Mississippi
Mississippi, MS

S. Roffler
Institute of Biomedical Sciences

P. Simerská
The University of Queensland

H.C.Lutz F. Tietze
University of Goettingen TammannstraBe

R.B. Walker (Biography
R.B. Walker

Professor R.B. Walker completed his Ph.D. degree in Biopharmaceutics and Pharmacokinetics at Rhodes University in Grahamstown, South Africa. He is the former Dean and Head of the Faculty of Pharmacy at Rhodes and is currently the Professor of Pharmaceutics and also the current Chair of the Academy of Pharmaceutical Sciences in South Africa. Prof. Walker has published and presented over 200 scientific outputs and serves on the editorial boards of a number of journals. Professor Walker undertakes research studies in all aspects of drug delivery and product development.


Rhodes University
South Africa

A. Williams
University of Bradford
Bradford, West Yorkshire

Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science